Department of Neurosurgery, Hôpital de la Timone, APHM, 13005 Marseille, France.
Sci Transl Med. 2012 Jan 11;4(116):116ps1. doi: 10.1126/scitranslmed.3003591.
2-Hydroxyglutarate (2-HG) is a potential oncometabolite involved in gliomagenesis that has been identified as an aberrant product of isocitrate dehydrogenase (IDH)-mutated glial tumors. Recent genomics studies have shown that heterozygous mutation of IDH genes 1 and 2, present in up to 86% of grade II gliomas, is associated with a favorable outcome. Two reports in this issue describe both ex vivo and in vivo methods that could noninvasively detect the presence of 2-HG in glioma patients. This approach could have valuable implications for diagnosis, prognosis, and stratification of brain tumors, as well as for monitoring of treatment in glioma patients.
2-羟戊二酸（2-HG）是一种潜在的致癌代谢物，参与胶质瘤的发生，已被鉴定为异柠檬酸脱氢酶（IDH）突变的神经胶质瘤的异常产物。最近的基因组学研究表明，IDH1 和 IDH2 基因的杂合突变，存在于高达 86%的二级胶质瘤中，与良好的预后相关。本期的两项研究报告描述了两种可以无创检测胶质瘤患者 2-HG 存在的体外和体内方法。这种方法可能对脑肿瘤的诊断、预后和分层以及监测胶质瘤患者的治疗具有重要意义。
